Skip to main content

Table 7 Clinicopathologic characteristics according to triple negative and non-triple negative breast cancer

From: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

   No. of Pts Triple negative (N = 47) Non-triple negative (N = 98) p-value*
Variables    No. of Pts (%) No. of Pts (%)  
Age < 50 102 33 (70.2) 69 (70.4) 0.981
  ≥ 50 43 14 (29.8) 29 (29.6)  
Performance ECOG 0–1 139 45 (95.7) 94 (95.9) 0.961
  ECOG 2 6 2 (4.3) 4 (4.1)  
Initial clinical stage IIA, IIB, IIIA 93 27 (57.4) 66 (67.3) 0.245
  IIIB, IIIC 52 20 (42.6) 32 (32.7)  
Inflammatory breast cancer Yes 18 4 (8.5) 14 (14.3) 0.425
  No 127 43 (91.5) 84 (85.7)  
Radiologic response Responder 100 39 (83.0) 61 (62.2) 0.012
  Non-responder 45 8 (17.0) 37 (37.8)  
pCR No 134 39 (83.0) 95 (96.9) 0.005
  Yes 11 8 (17.0) 3 (3.1)  
Adjuvant hormonal therapy Yes 63 0 (0.0) 63 (64.3) <0.001
  No 82 47(100.0) 35 (35.7)  
Radiation therapy Yes 128 41 (87.2) 87 (88.8) 0.787
  No 17 6 (12.8) 11 (11.2)  
Nuclear grade I, II 41 3 (8.1) 38 (41.8) <0.001
  III 87 34 (91.9) 53 (58.2)  
Histologic grade I, II 39 7 (20.0) 32 (37.2) 0.066
  III 82 28 (80.0) 54 (62.8)  
bcl-2 Positive 63 14 (31.8) 49 (52.7) 0.022
  Negative 74 30 (68.2) 44 (47.3)  
Ki-67 Low expression 56 13 (28.3) 43 (45.3) 0.053
  High expression 85 33 (71.7) 52 (54.7)  
p53 Low expression 67 22 (46.8) 45 (46.9) 0.994
  High expression 76 25 (53.2) 51 (53.1)  
  1. *based on Pearson's χ2 test (using Fisher's exact test if N ≤ 5)